Maxim Group Keeps a Buy Rating on Applied DNA Sciences (APDN)

By Austin Angelo

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Applied DNA Sciences (APDNResearch Report) yesterday and set a price target of $21.00. The company’s shares closed last Friday at $10.00.

According to, McCarthy is a top 100 analyst with an average return of 37.6% and a 53.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Applied DNA Sciences is a Moderate Buy with an average price target of $21.50, which is a 64.8% upside from current levels. In a report issued on July 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.69 and a one-year low of $2.52. Currently, Applied DNA Sciences has an average volume of 2.26M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied DNA Sciences, Inc. engages in the provision of security solutions. It offers molecular-based technology solutions and services that can help protect products, brands, supply chains, and intellectual property of companies, governments, and consumers from theft, counterfeiting, fraud, and diversion. Its products include the following brands: Applied DNA Sciences, SigNature, molecular tags, SigNature, T molecular tags, fiberTyping, DNAnet, digitalDNA, SigNify, BackTrac, Beacon, and CertainT. The company was founded in 1983 and is headquartered in Stony Brook, NY.